Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 2/20 | 0.53 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 2/20 | 0.41 |
| ▸ | CYP27A1 | Q02318 | 1/20 | 0.39 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4093483 | 0.88 | HSD17B1 (0.50) | HSD17B1METAP1ACHECYP19A1 | |
| SCHEMBL4095859 | 0.81 | HSD17B1 (0.57) | HSD17B1METAP1CYP27A1CYP24A1ACHE | |
| SCHEMBL4101697 | 0.79 | HSD17B1 (0.57) | HSD17B1ACHE | |
| SCHEMBL4102704 | 0.79 | HSD17B1 (0.55) | HSD17B1 | |
| SCHEMBL6272399 | 0.78 | METAP1 (0.65) | METAP1CYP27A1CYP24A1ACHECYP19A1 | |
| SCHEMBL4104783 | 0.78 | HSD17B1 (0.80) | HSD17B1 | |
| SCHEMBL11076729 | 0.78 | ACHE (0.56) | ACHE | |
| SCHEMBL4101945 | 0.72 | DGAT1 (0.64) | DGAT1CYP27A1CYP24A1CYP19A1PPARD | |
| SCHEMBL13774777 | 0.72 | DGAT1 (0.64) | DGAT1CYP27A1CYP24A1CYP19A1PPARD | |
| SCHEMBL9048859 | 0.72 | CYP19A1 (0.58) | DGAT1METAP1CYP24A1ACHECYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| EP-2013176-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | Sterix Limited (GB) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007096647-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | STERIX LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186900-A1 | COMPOUND | HSD17B2, HSD17B11, CYP17A1 | HSD17B1 4/4885DGAT1 1072/4885METAP1 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.